HPV-positive after immunotherapy
55R/M oropharynx HNSCC, HPV-positiveCPS 22, ECOG 0
HPV-positive: prognosis, or prediction?
5%
A guide to agent choice
96%
Information about his outlook
What matters now
Single-arm phase 2 data show investigational second-line agents producing response rates up to 60% after immunotherapy exposure.
55R/M oropharynx HNSCC, HPV-positiveCPS 22, ECOG 0
HPV-positive: prognosis, or prediction?
5%
A guide to agent choice
96%
Information about his outlook
70R/M oral cavity HNSCC, HPV-negativeslow progression on nivolumab
Sign the queued order, or check eligibility first?
64%
An eligibility check
36%
The plan, tolerance and approvals
67R/M hypopharyngeal HNSCCrepeat CPS 6 after pembrolizumab
CPS of 6: a live signal, or a first-line measure?
5%
A current immunotherapy signal
95%
A first-line selection tool
63R/M laryngeal HNSCC, HPV-negativetumor board recommends docetaxel
Docetaxel now, or a trial first?
14%
The established path
86%
Trials and newer agents
58R/M oropharynx HNSCC, HPV-positiveafter pembrolizumab, then cetuximab
His cetuximab history, or the new agent's criteria?
17%
His history and outside opinion
83%
The agent's own criteria
What matters now
Single-arm phase 2 data show investigational second-line agents producing response rates up to 60% after immunotherapy exposure.
5 Real World Scenarios
55R/M oropharynx HNSCC, HPV-positiveCPS 22, ECOG 0
HPV-positive: prognosis, or prediction?
Where does the evidence land?
5%
A guide to agent choice
96%
Information about his outlook
70R/M oral cavity HNSCC, HPV-negativeslow progression on nivolumab
Sign the queued order, or check eligibility first?
Where does the evidence land?
64%
An eligibility check
36%
The plan, tolerance and approvals
67R/M hypopharyngeal HNSCCrepeat CPS 6 after pembrolizumab
CPS of 6: a live signal, or a first-line measure?
Where does the evidence land?
5%
A current immunotherapy signal
95%
A first-line selection tool
63R/M laryngeal HNSCC, HPV-negativetumor board recommends docetaxel
Docetaxel now, or a trial first?
Where does the evidence land?
14%
The established path
86%
Trials and newer agents
58R/M oropharynx HNSCC, HPV-positiveafter pembrolizumab, then cetuximab
His cetuximab history, or the new agent's criteria?
Where does the evidence land?
17%
His history and outside opinion
83%
The agent's own criteria